Parkview Health | Parkview Research Center

Research site

Site insights

Top conditions

Top treatments


Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 65 total trials

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatmen...

Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Drug: Cisplatin
Drug: Gemcitabine

The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal...

Heart Failure NYHA Class II
Heart Failure NYHA Class III
Device: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download
Other: Medication intervention

This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with I...

Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T
Locations recently updated

This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or aft...

HPV-Related Cervical Carcinoma
HPV-Related Malignancy
Drug: Placebo
Biological: VB10.16

This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of eff...

Active, not recruiting
Endometrial Cancer
Drug: Matching placebo for selinexor
Drug: Selinexor

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting
Ovarian Neoplasms
Fallopian Tube Adenocarcinoma
Drug: Paclitaxel
Drug: Carboplatin

The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovasc...

Active, not recruiting
Abdominal Aortic Aneurysm
Device: FDA Approved EVAR AAA Graft Systems
Device: AFX EVAR AAA Graft System

RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to...

Active, not recruiting
Hypertension, Resistant to Conventional Therapy
Device: Renal Denervation

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional...

Hormone Receptor-positive Breast Cancer
Locoregional Recurrence
Drug: Fulvestrant
Drug: Anastrozole

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete...

Endometrial Cancer
Drug: Navtemadlin Placebo
Drug: Navtemadlin

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has s...

Active, not recruiting
Metastatic Solid Tumor
Drug: Sacituzumab Govitecan-hziy

This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (A...

Ischemic Stroke
Drug: Recombinant human tissue kallikrein

Trial sponsors

Abbott logo
Sumitomo Pharma logo
Gilead Sciences logo
Incyte logo
Boston Scientific logo
Celgene logo
NuVasive logo
Pfizer logo
Roche logo
AdventHealth logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems